FLORHAM PARK, N.J., September 07, 2023 Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), announced the upcoming presentation of new data at IDWeek 2023 (October 11-15, 2023) on its investigational oral antiviral for COVID-19, ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622, hereafter "ensitrelvir"), and Fetroja® (cefiderocol), an antibiotic marketed under the brand name Fetcro
Spanish researchers have identified several gold-based compounds with the potential to treat multidrug-resistant bacteria, or “superbugs”. The compounds were found to be effective against at least one hard-to-treat bacterium, with some proving effective against several.